Acrivon Therapeutics, Inc. Common Stock (ACRV) vs Cognition Therapeutics, Inc. (CGTX)
A side-by-side comparison of Acrivon Therapeutics, Inc. Common Stock and Cognition Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACRV
Acrivon Therapeutics, Inc. Common Stock
$1.94HealthcareDelayed quote: Oct 6, 2026, 12:45 PM EDT
CGTX
Cognition Therapeutics, Inc.
$0.94HealthcareDelayed quote: Oct 6, 2026, 12:43 PM EDT
Total return — ACRV vs CGTX
growth of $100 · dividends reinvested · last 4yACRV -88.1% (-41.3%/yr)CGTX -35.3% (-10.3%/yr)CGTX compounded faster over this window
Log scale — wide-divergence pair
ACRV CGTX
ACRV vs CGTX: by the numbers
- •CGTX is the larger company ($84M vs $83M market cap).
Metrics side by side
Valuation
| Metric | ACRV | CGTX |
|---|---|---|
| P/B ratio | 0.96 | 2.55 |
Profitability
| Metric | ACRV | CGTX |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -85.65% | -50.80% |
| ROIC | -88.28% | -109.43% |
Go deeper
Dig into the metrics
Acrivon Therapeutics, Inc. Common Stock ROECognition Therapeutics ROEAcrivon Therapeutics, Inc. Common Stock operating marginCognition Therapeutics operating marginAcrivon Therapeutics, Inc. Common Stock revenue growthCognition Therapeutics revenue growthAcrivon Therapeutics, Inc. Common Stock free cash flowCognition Therapeutics free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.